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Transcriptome assists prognosis 
of disease severity in respiratory 
syncytial virus infected infants
Victor L. Jong1,2,*, Inge M. L. Ahout3,*, Henk-Jan van den Ham2, Jop Jans3, Fatiha Zaaraoui-
Boutahar2, Aldert Zomer3, Elles Simonetti3, Maarten A. Bijl2, H. Kim Brand3, Wilfred F. J. van 
IJcken4, Marien I. de Jonge3, Pieter L. Fraaij2,5, Ronald de Groot3, Albert D. M. E. Osterhaus2,6, 
Marinus J. Eijkemans1, Gerben Ferwerda3 & Arno C. Andeweg2
Respiratory syncytial virus (RSV) causes infections that range from common cold to severe lower 
respiratory tract infection requiring high-level medical care. Prediction of the course of disease in 
individual patients remains challenging at the first visit to the pediatric wards and RSV infections 
may rapidly progress to severe disease. In this study we investigate whether there exists a genomic 
signature that can accurately predict the course of RSV. We used early blood microarray transcriptome 
profiles from 39 hospitalized infants that were followed until recovery and of which the level of disease 
severity was determined retrospectively. Applying support vector machine learning on age by sex 
standardized transcriptomic data, an 84 gene signature was identified that discriminated hospitalized 
infants with eventually less severe RSV infection from infants that suffered from most severe RSV 
disease. This signature yielded an area under the receiver operating characteristic curve (AUC) of 0.966 
using leave-one-out cross-validation on the experimental data and an AUC of 0.858 on an independent 
validation cohort consisting of 53 infants. A combination of the gene signature with age and sex yielded 
an AUC of 0.971. Thus, the presented signature may serve as the basis to develop a prognostic test to 
support clinical management of RSV patients.
Respiratory syncytial virus (RSV) causes infections that range from common cold to severe lower respiratory 
tract infection that in some instances may have a fatal outcome. Especially infants, elderly and patients with 
underlying chronic disorders suffer from severe RSV infections1,2. In infants, RSV is the leading cause of lower 
respiratory tract infections (LRTI) and is responsible for 80% of acute bronchiolitis cases3. RSV infections pose a 
huge burden on society in terms of disease, logistics and socio-economic sequelae. There is an unmet need for an 
RSV vaccine, despite considerable research efforts no licensed vaccine has been developed.
In industrialized countries, 1–5% of infants with RSV infection are hospitalized4–7. Some of these infants 
yet suffer from severe disease upon admittance, while others are admitted without severe symptoms since the 
course of bronchiolitis is highly variable and the need for supportive care cannot be predicted8,9. Several risk 
factors for developing severe RSV disease in infants have been identified, including preterm birth, young age, sex 
and environmental factors like in-house smoking10. Notwithstanding these known risk factors, current medical 
practice does not allow accurate prediction of whether an infant will further progress to severe RSV disease or 
not and could even be sent home safely. Genomic technologies have contributed to study the virus-host inter-
action, including virus discovery, pathogenesis studies, the design of antiviral strategies and identification of 
biomarkers to support clinical management of infectious diseases11–14. For RSV infections, this has supported 
the characterization of vaccine-induced skewed host responses upon infection15,16. Meijas et al.17 recently used 
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blood transcriptome profiles obtained within 3 days of hospitalization to characterize the host response to RSV 
infection in infants compared with rhinovirus or influenza infections and identified transcriptional profiles that 
associate with RSV disease severity. However, a prognostic model for RSV severity based on gene expression 
profiles collected at admittance to the hospital has not been developed.
In this study we aim to identify and validate a gene signature that discriminates severe from less severe RSV 
LRTI that do not require advanced support. Such a signature together with other clinical parameters may improve 
the prognosis of less severe patients that could be safely sent home.
Material and Methods
Study design. Study subjects were recruited at Canisius Wilhelmina Hospital, Radboud University Medical 
Center, Nijmegen, and Erasmus Medical Center, Rotterdam, The Netherlands. Nasopharyngeal wash and blood 
samples were prospectively obtained from patients less than 2 years of age with a viral bronchiolitis. Patient 
enrolment occurred 7 days a week and samples were taken within 24 hours after first contact with the hospital. 
Seventy-three percent of all eligible bronchiolitis patients agreed to participate in the study. The major reasons 
for non-inclusion were parental availability to sign consent and the hesitancy for the venipuncture. Only patients 
with an RSV infection, as retrospectively determined by PCR were included in the study. Exclusion criteria were: 
immunodeficiency, systemic steroid treatment in the previous 2 weeks, blood transfusion, congenital heart and 
chronic lung disease. A Tempus tube (TempusTM, Applied Biosystems, Austria) and sodium heparin tube were 
filled with 3 ml of blood. Medical history, demographic and clinical data were collected from medical records 
and questionnaires. The (hospitalized) patients were followed until recovery and were retrospectively classified 
as: mild for children without hypoxia, moderate for patients requiring supplemental oxygen (oxygen saturations 
< 90%, ≥ 10 minutes) and severe for children requiring mechanical ventilation due to apnea, exhaustion and/
or respiratory failure. Recovery samples were obtained after 4–6 weeks, during home visits. Blood samples were 
obtained from healthy controls (HC) without underlying diseases or medication subjected to elective surgery.
Study approval. The study protocol was approved by the Regional Committees on Research involving 
Human Subjects of Arnhem-Nijmegen and Rotterdam and were conducted in accordance with the principles 
of the Declaration of Helsinki. Written informed consent was obtained from the parents of all children prior to 
inclusion in the study.
Sample processing and blood transcriptome profiling. Inclusion of patients and sample collection 
was performed by a single MD at the hospitals. Multiplex RT-PCR was performed to test the nasopharyngeal 
washes on 15 different viral pathogens, as previously described18. Blood was collected in Tempus tubes for imme-
diate stabilization of RNA and subsequently stored at − 80 °C. Total RNA was isolated from each blood sample, 
processed, assessed, labelled and hybridized to a single Affymetrix Human Genome U133 plus 2 gene chips; and 
image analysis was performed in the same lab and by one technician as described in supplementary material. The 
raw data has been deposited in the ArrayExpress database under access number E-MTAB-5195.
Data preprocessing. Microarray data was preprocessed using R 3.1.2 19 and Bioconductor20. Upon ini-
tial quality control and VSN normalization (to render samples comparable), probeset (a combination of mul-
tiple probes) summarization was performed by median polish21,22. Unless otherwise stated, all probesets/genes 
present on the Affymetrix GeneChip were used for data analysis. Samples were labelled and hybridized in two 
batches which did not correspond to any biological variable as samples were randomly assigned to the batches. 
The normalized expression values were adjusted for a batch effect (see supplementary Fig. S1) using ComBat23. 
Additionally, we assessed confounding effects of clinical parameters age and sex on gene expression–severity 
relationship using “biasograms”24.
Differential expression analysis. To obtain a global view of the blood transcriptome changes in response 
to RSV infection (i.e. to evaluate whether whole transcriptome changes associate with severity), a principal com-
ponent analysis (PCA) as an exploratory analysis was performed on the age by sex standardized data. Next, a 
differential expression (DE) analysis was performed on the normalized-batch-adjusted data controlling for an age 
by sex effect using empirical Bayes linear models25 implemented in the R package limma26. Details of the models 
are found in supplementary material. We controlled for multiple testing via false discovery rate (FDR) using a 
Benjamini and Hochberg procedure27. Gene set enrichment analysis was performed using Ingenuity pathway 
analysis (IPA, www.qiagen.com/ingenuity).
Identification and evaluation of prognostic biomarkers. Since we are interested in identifying 
RSV-infected infants that will progress to severe stage upon presentation to the hospital, we grouped mild and 
moderate samples and aimed to separate these samples from infants that were presented with or progressed to 
severe disease after hospitalization. We chose to utilized probabilistic predictors (to predict the chance of an 
RSV-infected infant to be severe) because in clinical applications, probabilities are more informative than absolute 
yes or no predictions28. Several probabilistic predictors exist in the literature and their performance depends on 
the type of the data they are being applied on ref. 29. Using results of ref. 29,30 and observed correlations in the 
data, three probabilistic classification functions that could be optimal for this data were chosen as described in 
supplementary material. These functions were support vector machines (SVM)31, shrunken centroids discrimi-
nant analysis (SCDA)32 and random forest (RF)33.
For each classification function, the experimental data was split into a learning set and a test set using 
leave-one-out cross-validation (LOOCV). Cross-validation reduces optimistic bias by ensuring that our models 
are evaluated on an independent dataset that was not used to constructed these models. Most probabilistic clas-
sification functions require hyper-parameters to perform variable selection among the huge number of variables 
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(probesets). Usually, the best values for these hyper-parameters are also determined by cross-validation. Thus, 
the parameter(s) of the function were optimized using an inner loop of five-fold cross-validation on the learning 
set. Next, a prognostic model was built with the optimal parameter(s) on the entire learning set and evaluated 
with the test set, as described in supplementary material. The following R packages; CMA34, e107135, pamr36 and 
randomForest37 were utilized for class prediction. The best calibrated and refined function amongst the three 
functions was selected and its performance evaluated using the area under the receiver operating characteris-
tic (ROC) curve (AUC). Finally, the transcripts that maximized the binomial log-likelihood function, with the 
leave-one-out cross-validated data were retained as a gene signature from the selected function as described in 
supplementary material.
Comparison of biomarkers to clinical parameters. Age and sex are readily available clinical param-
eters that have been determined to be associated to RSV disease severity38. To assess the gain attained with a 
genomic model over a model with these clinical parameters, and the effect of standardization, the leave-one-out 
cross-validated predicted probabilities of progressing to severe for all samples were transformed to genomic 
scores (a genomic score is single measure of the genome of a sample as predicted by a model) for models with 
unstandardized and standardized data. Logistic regression models (see supplementary material) were then fitted 
with the genomic scores and/or clinical parameters and their AUCs compared.
Validation of biomarkers. For an independent validation, a subset of the Illumina RSV data of Meijas 
et al.17 was used. Since the experimental data and validation data were obtained using different platforms, we 
linked the data using gene symbols and applied cross-platform transformation (to render gene expression compa-
rable across datasets) as described in supplementary material. The transformed data was supplied to our prognos-
tic model for predictions of probabilities of severity. For a confirmatory analysis of how well our prognostic model 
performs, we built and evaluated a prediction model with the chosen function (same function used to build our 
prognostic model) on the entire Illumina data and compared our validation performance to the performance 
from this (unrestricted) data.
Results
Study subjects and sampling. Thirty-nine infants hospitalized with acute RSV bronchiolitis were included 
in the study. Nasopharyngeal wash and whole blood samples for mRNA profiling were collected within 24 hours 
upon hospital admittance. Table 1 presents the characteristics of the study subjects. As expected, patients with the 
most severe course of RSV bronchiolitis were significantly younger than those with a relative mild or moderate 
course of this disease. The variables related to disease severity; duration of oxygen, and length of stay in the hos-
pital were highest in the severe group, with ventilation indicating the method by which oxygen was supplied. The 
proportion of co-infections was lower in severe patients as compared to the other severity categories. There were 
no differences in the occurrence of other known risk factors.
Age and sex as confounders of gene expression–severity relationship. Figure 1a,b respectively 
illustrate the confounding effects of sex and age on the gene expression-disease severity relationship. These figures 
show that whereas age is negatively correlated to severity, sex is uncorrelated to severity. Nevertheless, the high 
positive/negative correlations of a considerable number of transcripts to sex and age, as well as severity, indicate 
a confounding effect of these variables on the expression-severity relationship of these transcripts, thus warrant 
adjustment. Figure 1d,e illustrate the “biasograms” after an age by sex standardization. These figures show that 
standardization has no effect on severity correlated transcripts but as expected, transcripts that were originally 
correlated to age and sex become uncorrelated. A positive correlation of age to sex which signifies an age by sex 
interaction as a potential confounder on the gene expression-severity relationship was also observed (Fig. 1c) and 
eliminated after standardization (Fig. 1f).
Global blood transcriptome profiles associate with RSV disease severity. Figure 2 illustrate a 
PCA on the whole transcriptome and the first principal component accounts for 25% of the variance in the 
Parameters Mild (n = 7) Moderate (n = 14) Severe (n = 18)
Age (days) 153 [84, 291] 185 [60, 333] 31 [17, 76]
Gestational age (weeks) 40 [29, 41] 40 [37, 41] 39 [37, 40]
Birth weight (kg) 3.5 [3.0, 4.2] 3.4 [3.1, 3.9] 3.3 [2.5, 4.0]
Symptomatic days 4 [2, 6] 4 [3, 6] 3 [2, 4]
Duration on O2 (days) 0 3 [2, 5] 8 [7, 11]
Ventilation None Supplemental Mechanical
Length of stay (days) 4 [2, 6] 5 [3, 8] 11 [9, 13]
Breastfeeding 4 (57) 11 (79) 12 (67)
Male gender 5 (71) 10 (71) 12 (67)
RSV + other virus(es) 4 (57) 8 (57) 3 (17)
Table 1.  Patient characteristics (n represents the number of samples per group). Data are presented as 
median and interquartile range (IQR) in square brackets [. ] or number and percentage in brackets ().The 
median age of the healthy controls was 536 days (IQR [472, 602]).
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transcriptomes and associates with disease severity. Transcriptome profiles of HC and recovery samples group 
together on the first principal component and are located opposite to profiles of severe infants. The distinct 
groups do not form discrete clusters in the PCA but gradually shift from mild through moderate to severe, with 
considerable overlap. This shows that the blood mRNA profiles substantially capture the severity of lower respira-
tory tract RSV infection.
Figure 1. Confounding effect of Sex, Age and Age by Sex on gene expression–severity relationship, before. 
(a,b,c) and after: (d,e,f), an age by sex standardization. The blue and green lines represent the clinical variables, 
the cosine of the angle between the lines represents its correlation to the blue line (Sex is not correlated to 
Severity, Age is negatively correlated to Severity i.e. younger kids become severe and Age is positively correlated 
to sex i.e. females are older). The cloud of points represent the transcripts and their correlations to both variables 
with most transcripts uncorrelated to the variables (yellow cloud) while a considerable number (black cloud) are 
correlated to Severity, Sex, Age and Age *Sex. The associations between the transcripts and Sex, Age or Age *Sex 
are significantly eliminated after standardization while retaining that of Severity.
Figure 2. Global blood transcriptome profiling with principal component analysis: the first principal 
component (PC1) accounts for 25% of the variance in the dataset and associates with disease severity. This 
can be observed as a shift from healthy controls and recovery cases (left) through mild and moderate to severe 
cases (right), with considerable overlap.
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Number of differential gene expression relates to RSV disease severity. Table 2 presents results of 
differential gene expression analysis and reveals that the number of DE transcripts increases with disease severity. 
No DE transcript was identified between mild versus HC samples when applying a FDR of 5% and absolute fold 
change (FC) threshold of 2. However, 17 and 221 transcripts were DE between moderate and severe versus HC 
respectively. Interestingly, all transcripts that are DE in moderate class are also DE in severe class with larger FC. 
About 90% of these DE transcripts are up-regulated. Comparison of HC with recovery samples revealed a single 
down-regulated transcript while moderate versus mild yielded no DE transcript, severe versus mild or moderate 
yielded 178 and 49 DE transcripts respectively. Lastly, 95 transcripts were DE between severe versus combined 
mild/moderate samples.
RSV induced blood transcriptome profiles reveal an inflammatory response. Figure 3 shows that 
multiple relevant categories of molecular and cellular functions are significantly enriched when comparing severe 
to HC samples. With “Cell-to-Cell Signaling and Interaction” top category, gene sets related to activation of sev-
eral types of immune cells including lymphocytes, granulocytes and specifically neutrophils are most significantly 
enriched. In addition, gene sets that are involved in migration and tissue infiltration of these same activated cell 
types are most significantly enriched within the category “Cellular Movement” that ranks third on this figure. 
Finally, several high ranking molecular and cellular function categories and their underlying gene sets indicate 
the immune cells involved are strongly proliferating. A list of genes involved in each of these pathways is pre-
sented in supplementary Table S1. Taken together, blood transcriptome changes in RSV disease reveal a typical 
inflammatory response to a viral infection.
Early blood transcriptome changes to predict a severe outcome of RSV infection. To construct 
a predictive model, we combined mild and moderate cases as a single group and three probabilistic classification 
functions were chosen based on supplementary Fig. S2 and results of Jong et al. and Kim and Simon29,30. Using 
these functions, classifiers were built and evaluated using LOOCV on the experimental data. SVM was chosen 
as the best calibrated and refined as shown on supplementary Fig. S3 and henceforth considered for all analy-
ses. The LOOCV predicted probabilities from SVM were used to evaluate its performance and are plotted on 
Fig. 4a against the true RSV status as retrospectively determined. This figure shows that 5 samples out of 39 were 
Mil-HC Mod-HC Sev-HC Mod-Mil Sev-Mil Sev-Mod RC-HC Sev-(Mil+Mod)/2
UP 0 15 194 0 164 42 0 82
Down 0 2 27 0 14 7 1 13
Total 0 17 221 0 178 49 1 95
Table 2.  Number of differentially expressed transcripts for each contrast at FDR of 5% and absolute fold 
change cutoff of 2. Where Mil: Mild, Mod: Moderate, Sev: Severe, HC: Healthy controls (< 2years) and RC: 
Recovery samples.
Figure 3. Ingenuity pathway analysis (IPA) Molecular and Cellular functions gene set analysis for severe vs 
healthy control contrast. 
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misclassified at a 50% cutoff and when applying a proposed uncertainty band of 30–70% just one false negative 
is witnessed. Evaluation of the clinical characteristics of the single false negative patient as well as those patients 
with uncertain predictions (plotted within the proposed uncertainty band) did not reveal any recognizable pat-
tern. The false negative patient had uniquely RSV and only a single patient plotted within the uncertainty band 
had RSV+ other virus(es). Figure 4b presents the corresponding ROC curve from the LOOCV predicted proba-
bilities and AUC of 0.966 demonstrates the high discriminative power of our prognostic model.
Genomic biomarkers outperform clinical parameters age and sex. Figure 4c presents the ROC 
curves from logistic models of clinical parameters and/or genomic scores. The genomic score model from the 
standardized data (AUC = 0.966) outperforms that from the unstandardized data (AUC = 0.915). In addition, 
there is a significant difference between a model with age and sex only (AUC = 0.833) and that with a standard-
ized (AUC = 0.966) or unstandardized genomic score (AUC = 0.915). Whereas there is a slight improvement 
from clinical parameters and standardized genomic score model (AUC = 0.971), there is no improvement from 
the clinical parameters and unstandardized genomic score (AUC = 0.911), indicating that indeed standardization 
completely removed an age-by-sex effect on the gene expression data.
An 84 gene expression signature predicts absence of disease progression. To extract the prog-
nostic signature, we selected top transcripts maximizing the binomial log-likelihood function using LOOCV 
predicted probabilities as illustrated on supplementary Fig. S4. This figure depicts a 1-SE maximum of 95 tran-
scripts corresponding to 84 unique genes, which are displayed on Table 3. Of the 95 transcripts constituting the 
prognostic signature, 81 (85.26%) were found to be significantly DE between severe and non-severe patients 
(FDR cutoff of 5%, supplementary Table S2). The inclusion of non-DE transcripts in the classification model is 
expected, since not only DE genes are instrumental in class discrimination as illustrated by the two-dimensional 
scenario in supplementary Fig. S5.
Performance of the genomic signature retained on an independent dataset. For an independent 
validation, a subset of the Illumina RSV data of Meijas et al.17 was used. Since the experimental data and validation 
data were obtained using different platforms, we linked the data using gene symbols and applied cross-platform 
transformation (to render gene expression comparable across datasets) as shown on supplementary Fig. S6 and 
extensive described in the supplementary material. Figure 5a presents predicted probabilities of severe on the val-
idation data using 75 of our 84 prognostic gene signature that were common in both experimental and validation 
datasets, while Fig. 5b presents the LOOCV predicted probabilities from SVM on the entire Illumina data. Both 
figures show that using the unrestricted data leads to more certain probabilities and slightly improves specificity 
Figure 4. Internal validation of gene signature. (a) samples’ predicted probabilities of being severe.  
(b) shows the ROC curve and the AUC for predicted probabilities. The AUC value of approximately 1 indicates 
how accurate our signature performs on this internal validation set. (c) shows that a genomic model from 
the age by sex standardized data out performs that from the unstandardized data. In addition, there is a 
significant difference between a model with clinical parameters and that with a genomic score and just a slight 
improvement when both parameters are included in a model.
www.nature.com/scientificreports/
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No Affymetrix IDs Gene Symbol Illumina IDs
1 1553605_a_at ABCA13 0pf.QRwb4sWsn7jQKQ
2 238439_at 239196_at ANKRD22 oXed_glbkhVEMCDCTo xnW5awXa6P_EbICH0s HIf_t7qU.BejlFP86o
3 209369_at ANXA3 orojh4FCCMN1ArUY6k
4 205678_at AP3B2 9SneFS4fUDnuF7_nVM
5 206632_s_at APOBEC3B 9Ff619hplIXH7nOK6I
6 206177_s_at ARG1 0lVMTIuod_g0ohAnFE
7 232197_x_at ARSB 3IDh9IVCveAqVdCl2o cMniVI7195NdYNUqeo BJIKm4IFqJ01E3eHp4 0u0lM7OqfU.quOIC94
8 201242_s_at ATP1B1 unu3iN6N5U0f6cuEqc 9pU2OJP.BMdTLf9e64 fvOfs_Dnt_E3fl_11o
9 214575_s_at AZU1 QBuHuFVihS7ZVBBu5E
10 221530_s_at BHLHE41 EUN35CXUp3p.txedvU
11 205557_at BPI EqRaeX9VKg13UjfBQg
12 210244_at CAMP rItcu7lcV6dKfep3iA
13 209498_at 211889_x_at CEACAM1 KpCYUm43RIkQFdLdQU fr.cFeEaHuTH9XTU54 xKXCKf3Uoo8n6L3cx0
14 203757_s_at 211657_at CEACAM6 9criZPiUuucDnEx1B4
15 206676_at CEACAM8 ubtBVA.8bOI1.LUVDo
16 209395_at 209396_s_at CHI3L1 Zn_tzf4mVHIVHodF1U
17 208168_s_at CHIT1 NA
18 220496_at CLEC1B uSC2Dit6C6ijp2vN0g
19 208146_s_at CPVL cdfjqToegKNUoMQgpI ZeEuC6evE1pCauH1NI
20 210262_at CRISP2 ukOTfdVSNNEgNH9KQ4
21 207802_at CRISP3 uqDXiAQ0SFE4hwohO4
22 205653_at CTSG 0RKUnUS75SJfDAbUSI
23 202859_x_at CXCL8 3Vy3nJSjUQtfvUe5fo EVLftPlJ7vrLnu_Dxo
24 207269_at DEFA4 6530r9KdBCqTred_SM
25 206871_at ELANE NtF0nlRFRHdSTekQwE
26 224225_s_at ETV7 9KCUpFjIkVJVFXsDoM
27 213506_at F2RL1 BSHqBKlSg3u6xAXk64 ZAl9Iq.oUTd.oAy.kE
28 211734_s_at FCER1A WgUoCn0h94FRNcJQFU
29 231093_at FCRL3 KV7kDSLO4uggquLXB4 ZUclXxUi6VEoBJeRT8 67unrLpPnjv_uzOezU
30 205110_s_at FGF13 Hd7t51A7ISQ_3qyhSc Hvun37sCEoHuge477c TmCOYpTxe.jV7aAXpE
31 223836_at FGFBP2 xmX900n31irhK4CFXE
32 223767_at GPR84 ok0Fe53OSU4FlD1lCQ
33 210321_at GZMH rgmXcEkpOIcF9d6l4U
34 206647_at HBZ lteivVSVR8WbDmUMBQ
35 213537_at HLA-DPA1 NFtdNMC3eb3pThValQ
36 203290_at HLA-DQA1 NA
37 209480_at HLA-DQB1 TfXanqXzTU0Si0gKnU
38 206697_s_at HP fpPOCkkS1WAIIRYIlc
39 215118_s_at IGH NA
40 212592_at IGJ HhecR84SAQucRJ7rVE
41 217148_x_at IGLC1 NA
42 234764_x_at IGLV1-44 NA
43 227140_at INHBA cp0iOCS4CISg_oqAqI
44 206494_s_at 206493_at 216956_s_at ITGA2B H3o0v7nktkZOvQbtdU
45 212531_at LCN2 WUTbfV7VDYUuzYaeLk
46 208450_at LGALS2 WT6GkkHqpCBBqCNF7k
47 222196_at LOC389906 NA
48 238717_at LOC441528 NA
49 1569110_x_at LOC728613 NA
50 202018_s_at LTF cQO5fddUoFsfScd65c
51 244523_at MMD 6p_X8jaueM_Xv1yw6k
52 207329_at 231688_at MMP8 fgvcFUrFTg7ifFKt.k BelT8r_h3KIiQoopKI
53 203936_s_at MMP9 fn3Hpm4vVouL4FK6FA
54 203949_at 203948_s_at MPO KXq9Q16d7p_cnO4× 4k
55 229510_at MS4A14 QqQF0qheQ0ghuCkj.Q 0JYKEkJ0rogLlAHvOU
Continued
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compared to our signature. Nonetheless, Fig. 5c illustrates a large agreement between the predicted probabilities 
of the two models, while Fig. 5d clearly reveals that both models are alike as demonstrated by the AUCs of 0.858 
and 0.856 for our signature and the unrestricted model respectively. To assess the concordance of the expression 
patterns of our signature on both datasets (Affymetrix and Illumina), we plotted the log2 fold changes of the 
common 75 genes as shown on Fig. 6. From this figure, one clearly sees that there is a huge concordance in the 
direction of expressions across datasets. Where there are slight differences, these differences are not significant as 
shown by a non-significant p-value in at least one of the datasets.
Discussion
RSV infection in infants may cause life-threatening disease. No vaccine is yet available and triage of patients is 
challenging since RSV infections may rapidly progress to severe disease. No reliable prognostic model to predict 
which RSV patient will not progress to severe disease and could be safely send home is available either. Thus, 
clinical care is symptom-based and a significant proportion of RSV infected infants is hospitalized for observation 
purposes. We have provided an 84 gene signature that discriminates hospitalized infants with less severe RSV 
infection from those infants with severe RSV disease. The identified signature yielded a LOOCV AUC of 0.966 
on the experimental data and was independently validated with an AUC of 0.858 and might serve as a basis to 
develop a prognostic test for clinical management of RSV disease.
In line with epidemiological observations38 and observations of Mejias et al.17, we showed the confounding 
effects of age and sex on gene expression-severity relationship for RSV disease. Studies in any RSV patient cohort 
with a naturally occurring “skewed” distribution of age and sex can be standardized for these parameters. By 
adjusting for an age-by-sex effect in our analyses, we obtained age-by-sex independent results which can be 
effectively applied to any patient(s). The high performance of our signature on the age and sex matched validation 
data signifies age-by-sex independence and robustness of this signature. Fewer co-infections were observed in 
severe patients (Table 1). A similar trend has been described previously39. In our cohort study we did not take into 
account co-infections since no consistent association between the occurrence or absence of co-infections with 
RSV disease severity have been reported39–43. Furthermore, we aimed at the identification of a gene signature in a 
natural “real-life” cohort of patients not stratified according to age or occurrence of co-infections.
No Affymetrix IDs Gene Symbol Illumina IDs
56 210254_at 1554892_a_at MS4A3 lKdKj.P0uB56B0ROV4 Qen_rt.er1_QxUxR9Q B3q9A94B7R88Xs4E6k
57 201058_s_at MYL9 Tbs1URA5CdFCtV3S1U 3CBVEhgxeipOOJilWo
58 209290_s_at NFIB BNHPXrzdFBgpyimm0g QUlzHnJJ50× 5LQ8egk
59 221690_s_at NLRP2 EFIl20d6F6tINX6rcs
60 206343_s_at NRG1
ruNF5QODCEECIJIKkI EX0VFaBXiuIGVC0kHQ rcTUUeoQlN_
wDuaIKI 9QpESNQOTkjUnNJB00 uX15cu4f_VUIuXoST0 
ZZlmuuNioCuRWSaaSQ
61 212768_s_at OLFM4 rgjyBSHxwUPUVVFBVc c70LXLcyj6S.A5.HVU
62 210004_at OLR1 9V0C7RDnXXjh11UgBQ
63 205040_at ORM1 fG6ilCJP2dH5410qEU
64 227474_at PAX8-AS1 NA
65 225207_at PDK4 ESC1yEuE.fDrqLUnTk
66 207384_at PGLYRP1 3mxHd1KQUncUXTUg_k
67 41469_at 203691_at PI3 NeHlSg0ILnuCnfmo6U
68 207341_at PRTN3 EX243qjuUVl.1eH30Y
69 211748_x_at 212187_x_at PTGDS HXlUBYwuThoEModVKk
70 220570_at RETN Qz8qQwkk_l6LlIm0XU
71 206851_at RNASE3 9aLI9auX8dR7hdMDUo
72 213566_at RNASE6 Te4VV0giY1VcQvr17E
73 214539_at SERPINB10 f0LQV4ks6o4uOX0lAk
74 1553177_at SH2D1B 0TlE1O9_rTf.5× 9Oi0
75 219519_s_at SIGLEC1 iiFGSdPjXjklE7iF0E
76 220000_at SIGLEC5 Q13VUdxtx69ahqiNUw oJC4o.lSL0tenoolEk
77 203021_at SLPI No174RVAVBCigl6guU
78 202286_s_at TACSTD2 WihIT5WgHS3Pz30n5U
79 205513_at TCN1 i4uimBR4lCiesvG_1k
80 209651_at TGFB1I1 EJXHlJXn14J32nhJWc iJVfHqoq1_Q9SYNopQ
81 219410_at TMEM45A 6qievf0j6P7Xs1VS6I r_iBJ6cKOHcLse.k.U
82 206641_at TNFRSF17 iWCth3hT5.UdUnOigo
83 218876_at TPPP3 ENZUufqUJFe6TUJ1Xo QLe5eyXThVBUlUpOnA
84 231122_x_at ZDHHC19 69eJXi6CX97l_V.lR0
Table 3.  Gene signature of 95 transcripts (probesets) corresponding to 84 genes.
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We hypothesized that changes in blood cell type distribution and/or mRNA expression changes of the cir-
culating cells collected from peripheral blood reflect local lung host response characteristics that associate with 
disease severity. PCA and DE analysis indeed revealed significant changes in the transcriptome profile of whole 
Figure 5. Predicted probabilities of being severe from the validation data against true RSV status using; our 
diagnostic signature (a) and LOOCV on unrestricted data (b). (c) illustrates the agreement of the predictions 
from both models, green regions are perfect agreement, blue are disagreements at a 50% cutoff and red are 
disagreements at a 30–70% uncertainty band. Finally, (d) presents the ROC curves and AUC from both models 
illustrating similar AUC values.
Figure 6. Log2 Fold change between Severe vs Non-Severe infants for 75 common genes in Affymetrix and 
Illumina datasets. Red represent up-regulation while green represents a down-regulation and the significant 
FDR adjusted p-values are placed in the cells. As one can clearly see, there is a huge overlap in the direction 
expressions across datasets. Where there are slight differences, these differences are not significant as shown by a 
non-significant p-value in at least one of the datasets.
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blood. Gene set analysis further shows that relevant processes are monitored including the activation, migration 
and tissue infiltration of lymphocytes, granulocytes and neutrophils. Individual DE genes in severe RSV dis-
ease revealed overexpression of the neutrophil associated genes MMP8 and MMP9, which have previously been 
related to severe RSV disease44. ARG1 and CHI3L1 that have been linked to alternatively activated macrophages 
in a mouse model for vaccine enhanced RSV disease16 were also found to be strongly up-regulated. This suggests 
that the collected blood transcriptome profiles indeed reflect local lung host response.
In our class prediction analysis, three functions were evaluated and the best was chosen. While it has been 
pointed by45–48 that selecting a minimal-error classifier leads to selection bias that should be corrected, the lit-
erature does not stipulate a selection bias when using calibration and refinement scores as evaluation measures. 
Nevertheless, we employed the nested cross-validation correction of selection bias46 in our model building pro-
cedure by splitting our experimental data into learning and test sets with an inner loop split on the learning set 
for parameter(s) optimization. Though found to contain high variance, we utilized leave-one-out cross-validation 
for the test set because it yields approximately an unbiased estimate of the true (expected) prediction error49 
and because we were interested in the individual sample predicted probability of severe and not entirely on the 
expected predicted error. Nevertheless, where we were interested in the expected predicted error, as in the opti-
mization of parameters, we utilized five-fold cross-validation as recommended by Breiman and Spector50. To val-
idate the identified signature, an independent dataset generated on a different platform was used. Despite (i) the 
several sources of variability between our experimental data and the validation data that stem from - but not lim-
ited to - array platforms and different clinical cutoffs of RSV severity statuses, (ii) different time of profiling, 1–3 
days after hospitalization and (iii) loss of information due to a reduction in signature because of no corresponding 
transcripts on Illumina platform and the aggregation of multiple transcripts to genes, our signature yielded an 
AUC of 0.858 that was comparable to accuracy (AUC of 0.856) when using the Illumina data (validation set) as 
experimental set. Cross-platform validation is rare due to lack of guidance on how this can be done reliably. We 
presented a cross-platform validation procedure.
The RSV patients enrolled in the study displayed varying disease severities but were all hospitalized thus rep-
resenting a severe disease enriched subset of RSV infected infants. The patients enrolled however also represent 
a natural cohort of patients including a significant number of patients that eventually did not require extensive 
medical care and could have been discharged home. Since the blood samples were collected soon after hospital 
admission, the generated blood transcriptomes and the derived gene signature may serve as a basis for the devel-
opment of a novel genomic tool to support clinical management of RSV disease including triage of patients pre-
senting at the hospital provided that a rapid (real time) gene test can be developed. Larger transcriptome data sets 
are however required to construct predictive models that may also allow for discriminating mild from moderate 
and moderate from severe cases. Ultimately, one would like to extend the RSV biomarker program to earlier time 
point samples (e.g. obtained when visiting a general practitioner) and to samples collected from patients infected 
by other (respiratory) infectious agents or pathological conditions (comorbidities) in order to identify specific 
respiratory viral prognostic biomarkers. To this end a novel gene signature have to be developed using a much 
larger early blood sample cohort. The current results support the development of diagnostic tests for personalized 
medicine that not only provide information on the causative infectious agent, but also about the disease severity 
that may be expected.
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